دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
Christophe E. M. De Block MD, Eveline Dirinck MD, Ann Verhaegen MD, Luc F. Van Gaal MD
doi : 10.1111/dom.14640
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment
Juris J. Meier MD, Daniel R. Quast MD, Michael A. Nauck MD, Nina Schenker MD, Carolyn F. Deacon DMSci, Jens J. Holst DMSci, Leona Plum-Mörschel MD, Christoph Kapitza MD
doi : 10.1111/dom.14636
Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial
Marlies Antlanger MD, Oliver Domenig PhD, Christopher C. Kaltenecker PhD, Johannes J. Kovarik MD, Vincent Rathkolb MD, Martin M. Müller MD, Elisabeth Schwaiger MD, Manfred Hecking MD, Marko Poglitsch PhD, Marcus D. Säemann MD, Chantal Kopecky PhD
doi : 10.1111/dom.14639
Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease
Glenn M. Chertow MD, Priya Vart PhD, Niels Jongs PhD, Anna Maria Langkilde MD, John J. V. McMurray MD, Ricardo Correa-Rotter MD, Peter Rossing MD, C. David Sjöström MD, Bergur V. Stefansson MD, Robert D. Toto MD, David C. Wheeler MD, Hiddo J. L. Heerspink PhD
doi : 10.1111/dom.14641
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period
Caroline Reilhac PhD, Julie Dubourg MD, Carole Thang PharmD, Jean-Marie Grouin PhD, Pascale Fouqueray MD, Hirotaka Watada MD
doi : 10.1111/dom.14642
Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVAC-DM cohort study
Caren Sourij MD, Norbert J. Tripolt PhD, Faisal Aziz MSc, Felix Aberer MD, Patrick Forstner MD, Anna M. Obermayer MD, Harald Kojzar BSc, Barbara Kleinhappl, Peter N. Pferschy MSc, Julia K. Mader MD, Gerhard Cvirn MD, Nandu Goswami MD, Nadine Wachsmuth PhD, Max L. Eckstein PhD, Alexander Müller MSc, Farah Abbas, Jacqueline Lenz, Michaela Steinberger, Lisa Knoll BSc, Robert Krause MD, Martin Stradner MD, Peter Schlenke MD, Nazanin Sareban MD, Barbara Prietl PhD, Susanne Kaser MD, Othmar Moser PhD, Ivo Steinmetz MD, Harald Sourij MD, COVAC-DM study group
doi : 10.1111/dom.14643
Reduction of clinically important low glucose excursions with a long-term implantable continuous glucose monitoring system in adults with type 1 diabetes prone to hypoglycaemia: the France Adoption Randomized Clinical Trial
Eric Renard MD, Jean-Pierre Riveline MD, Hélène Hanaire MD, Bruno Guerci MD, on behalf of the investigators of France Adoption Clinical Trial
doi : 10.1111/dom.14644
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
Lawrence A. Leiter MD, Maciej Banach MD, PhD, Alberico L. Catapano MD, PhD, P. Barton Duell MD, Antonio M. Gotto Jr MD, DPhil, Ulrich Laufs MD, PhD, G. B. John Mancini MD, Kausik K. Ray MD, DPhil, Jeffrey C. Hanselman MS, Zhan Ye PhD, Harold E. Bays MD
doi : 10.1111/dom.14645
Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study
Yogesh Yadav MD, Kelly Dunagan RN, Rachita Khot MD, Sudhakar K. Venkatesh MD, John Port MD, Alfonso Galderisi MD, Claudio Cobelli PhD, Craig Wegner PhD, Ananda Basu MD, Rickey Carter PhD, Rita Basu MD
doi : 10.1111/dom.14646
Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy
Luisa Ojeda-Fernández PhD, Andreana Foresta MSc, Giulia Macaluso MSc, Pierluca Colacioppo MSc, Mauro Tettamanti MSc, Antonella Zambon MSc, Stefano Genovese MD, Ida Fortino MSc, Olivia Leoni MSc, Maria Carla Roncaglioni MSc, Marta Baviera Pharm Dr
doi : 10.1111/dom.14648
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)
Olga Lavynenko MD, Muhammad Abdul-Ghani MD, Mariam Alatrach MD, Curtiss Puckett PAC, John Adams MS, Siham Abdelgani MD, Naim Alkhouri MD, Curtis Triplitt PharmD, Geoffrey D. Clarke PhD, Juan A. Vasquez BS, Jinqi Li MD, Eugenio Cersosimo MD, Amalia Gastaldelli PhD, Ralph A. DeFronzo MD
doi : 10.1111/dom.14650
ZT-01: A novel somatostatin receptor 2 antagonist for restoring the glucagon response to hypoglycaemia in type 1 diabetes
Rawad Farhat MD, MPH, Julian Aiken PhD, Ninoschka C. D'Souza MSc, Daniel Appadurai PhD, Grayson Hull BSc, Eric Simonson PhD, Richard T. Liggins PhD, Michael C. Riddell PhD, Owen Chan PhD
doi : 10.1111/dom.14652
Waist circumference thresholds predicting incident dysglycaemia and type 2 diabetes in Black African men and women
Julia H. Goedecke PhD, Kim A. Nguyen PhD, Clement Kufe MSc, Maphoko Masemola MSc, Tinashe Chikowore PhD, Amy E. Mendham PhD, Shane A. Norris PhD, Nigel J. Crowther PhD, Fredrik Karpe MD, Tommy Olsson MD, Andre Pascal Kengne PhD, Lisa K. Micklesfield PhD
doi : 10.1111/dom.14655
Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease
Jinnie J. Rhee ScD, Jialin Han MS, Maria E. Montez-Rath PhD, Sun H. Kim MD, Mark R. Cullen MD, Randall S. Stafford MD, Wolfgang C. Winkelmayer MD, ScD, Glenn M. Chertow MD
doi : 10.1111/dom.14657
Understanding the inter-relationships of type 2 diabetes and hypertension with brain and cognitive health: A UK Biobank study
Danielle Newby PhD, Victoria Garfield PhD
doi : 10.1111/dom.14658
Persistence with insulin pump therapy among children and young adults with type 1 diabetes in Germany: An update
Louisa van den Boom MD, Karel Kostev PhD
doi : 10.1111/dom.14647
Baseline blood pressure modifies the role of blood pressure variability in mortality: Results from the ACCORD trial
Daniel S. Nuyujukian PhD, Michelle S. Newell MS, Jin J. Zhou PhD, Juraj Koska MD, Peter D. Reaven MD
doi : 10.1111/dom.14649
The beneficial effects of closed-loop insulin delivery in patients with highly unstable type 1 diabetes eligible for islet transplantation are maintained over 6 months: An extension study of the DBLHU-WP10 trial
Pierre-Yves Benhamou MD, Sandrine Lablanche MD, Anne Vambergue MD, Sylvie Pou PhD, Stéphanie Madrolle PhD, Hector Romero-Ugalde PhD, Sylvia Franc MD, Guillaume Charpentier MD
doi : 10.1111/dom.14654
Mediators of the effects of canagliflozin on N-terminal pro-brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial
Atsushi Tanaka MD, Takumi Imai PhD, Makoto Suzuki MD, Shinya Hiramitsu MD, Naohiko Takahashi MD, Toshiaki Kadokami MD, Arihiro Kiyosue MD, Masami Nishino MD, Yasushi Sakata MD, Koichi Node MD, on behalf of the CANDLE trial investigators
doi : 10.1111/dom.14656
